Repair of N-methylpurines in DNA from lymphocytes of patients with amyotrophic lateral sclerosis.
We have previously reported reduced ability of ALS fibroblasts to repair genomic DNA damage produced by alkylating agents. This report presents our experience of studying DNA repair in lymphocytes from ALS patients. The repair of N-methylpurines produced by treatment with the alkylating agent, methyl methanesulfonate, was studied in T-lymphocytes from patients with sporadic and familial ALS, and appropriate controls. Repair of damage was quantitated by using alkaline elution for genomic DNA repair, and methoxyamine protection of abasic sites in DNA fragments for gene-specific repair in the dihydrofolate reductase (dhfr) gene, at time points 0, 6 h and 24 h. No significant repair rate differences were observed between ALS and control lymphocytes in either genomic or gene-specific DNA repair. The possible reasons for the discrepancy with our earlier results in lymphocytes and fibroblasts are discussed.
Robison
S H
SH
Department of Neurology, University of Vermont College of Medicine, Burlington.
Tandan
R
R
Bradley
W G
WG
D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000378:metabolism*; D002470:Cell Survival; D004247:DNA / Q000378:metabolism*; D004260:DNA Repair; D005260:Female; D006801:Humans; D008297:Male; D008741:Methyl Methanesulfonate / Q000494:pharmacology; D008875:Middle Aged; D011685:Purine Nucleotides / Q000235:genetics*; D013601:T-Lymphocytes / Q000378:metabolism* / Q000502:physiology; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics
D011685:Purine Nucleotides; D004247:DNA; D008741:Methyl Methanesulfonate; D013762:Tetrahydrofolate Dehydrogenase